Real-World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan.

Stratified PFS analysis by treatment line showed a trend toward longer PFS in earlier treatment lines: the median PFS was 21.3 months for first‐line treatment ( n = 5), 9.0 months for second‐line treatment ( n = 13), and 5.8 months for third‐ or later‐line treatment ( n = 9); however, these differences were not statistically significant ( p = 0.171) (Figure 2 ).

also in 53,322 other papers